Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo labeling deferrals

This article was originally published in The Tan Sheet

Executive Summary

FDA grants private labeler's request for varying deferral dates from OTC labeling final rule, depending on when agency labeling templates become available (1"The Tan Sheet" Oct. 1, p. 3). In Dec. 11 letter, FDA concludes that based on amount of time it has taken to finalize labeling templates for several ANDA drug products, "we consider your timetable for concurrent implementation of labeling revisions for [these] products to be appropriate." Implementation deferrals apply to clemastine fumarate tablets, doxylamine succinate tablets, pseudoephedrine HCl extended release and minoxidil topical solution, all of which did not have finalized FDA labeling templates as of Oct. 1...

Related Content

Topics

UsernamePublicRestriction

Register

PS093442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel